TRPV3 and skin disorder: To further confirm the role of downstream NF-κB signaling in dorsal skin inflammation, we topically coapplied TRPV3 agonist Car with the NF-κB signaling inhibitor JSH-23 (20 μM) in 100 μl to mouse dorsal skin for consecutive 4 days and observed a significant alleviation of the dorsal skin inflammation (Fig. 8G) and reduction of of dermatitis scores (Fig. 8H).